We are very happy that LS CancerDiag has been selected to be part of the first cohort of the X-Europe programme – HealthTech, MedTech and BioTech! LS CancerDiag is proud to have been selected from the
We are delighted to announce that LS CancerDiag has been selected as a participant to the EIT Health Bridghead Global programme! The Bridgehead programme provides European start-ups and scale-ups with individualised support in growing their
Back in January when we were living in a different world, our CBO Philippe Arnez talked with Logan Plaster at the StartUp Health Festival in San Francisco. You can watch the full interview below which
Lynch syndrome. Even though it is the most common hereditary cancer syndrome in the world, it is mostly unknown. Lynch syndrome prevalence is currently estimated at 1 in 279 globally[1], meaning that in Europe alone
We are living through truly unprecedented times. As a company we are taking all the necessary precautions to keep our employees safe, while continuing to serve our customers. However, we also want to take a
LS CancerDiag gets the patent granted in Brazil for its innovative DiagMMR® test. The largest country in Latin America completes the already impressive patent portfolio of LS CancerDiag. Brazil brings the total count to 29
Back in January, our CBO Philippe Arnez spent two days at the Startup Health Festival in San Francisco. LS CancerDiag is proud to be part of this dynamic and inspiring community. We are glad to
LS CancerDiag looks back on the year marked by the achievement of major milestones. 2019 started off with obtaining the CE mark for DiagMMR® as in vitro diagnostic medical device (IVD MD), enabling commercialization in
The last year of this decade has been a very successful one for LS CancerDiag, where many important milestones were achieved, and the basis was laid for strong growth over the coming years. To gear
We are excited to announce that Minttu Kansikas has been appointed as Chief Scientific Officer to lead the research efforts and laboratory functions. Congratulations! Minttu is a co-inventor and one of the leading scientists behind
”Only 24 #Lynchsyndrome carriers need to be treated with 600 mg/day aspirin to prevent one colorectal cancer”
There’s a NNT to remember.
@CaPP3 @Lynch_Fi @MattYurgelun @AndyChanMD @GabrielaMoslein @EHTG_Tweets @SoMe4GenRisk @ASCAP_QMUL @Lynchsyndromirl
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30973-9/fulltext
Thank you @xeuropeproject and @thenextweb for a great online kick-off event! #MedTech #Startup #DiagMMR #nordicinnovation #CancerPrevention
Great morning today! 👌 We're glad to see so many happy faces during the @xeuropeproject's kick off webinar, where the selected startups & scaleups were introduced to the next steps of the programme! 👏🔝
We are proud to be amongst the selected startups for the 1st cohort of @xeuropeproject! #medtech #diagmmr #lynchsyndrome #cancerprevention
Announcing the 27 selected startups & scaleups that just joined the first cohort of the X-Europe programme: HealthTech & BioTech! Congratulations to all 👏
Get to know them and their innovative solutions 👉 https://www.xeurope.eu/portfolio
@appercell @CievertLtd @iLoF_tech
We are thrilled and proud to have been selected to the Bridgehead Global programme by EIT Health!
We are very much looking forward to explore opportunities and get ready for markets beyond Europe! #eithealth #bridgehead #diagmmr #lscancerdiag
https://eithealth.eu/news-article/bridgehead-global-will-help-21-firms-expand-beyond-europe/
